Skip to content
Demo
‹ Back to IndustriesHealthcare

The Inspirational Quest to Eradicate Cancer

The world-renowned Thoracic Oncologist, Dr. Gerold Bepler, joined I Don’t Care’s Kevin Stevenson for a conversation that was no less than inspirational. Dr. Bepler, President and CEO of the Karmanos Cancer Institute, has a mission; to eradicate cancer. It’s more than a dream for Dr. Bepler; he believes it will be a reality one day….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The world-renowned Thoracic Oncologist, Dr. Gerold Bepler, joined I Don’t Care’s Kevin Stevenson for a conversation that was no less than inspirational. Dr. Bepler, President and CEO of the Karmanos Cancer Institute, has a mission; to eradicate cancer. It’s more than a dream for Dr. Bepler; he believes it will be a reality one day.

Dr. Bepler arrived from Germany to the United States in 1983. Following a post-doctoral fellowship at the National Cancer Institute, the starting point for his journey into lung cancer research. This career path took Dr. Bepler through many stops along the way, and in 2010 he joined the Karmanos Cancer Institute.

The mission to eradicate cancer got a boost in 1971 with the National Cancer Act, and Dr. Bepler said there’s tremendous progress towards this goal since that point. “People now diagnosed with cancer have hope,” Dr. Bepler said. “And many of them get cured of the disease and have a good quality of life. That all wouldn’t have been possible without the National Cancer Act.”

Much of the progress made to eradicating cancer at the Karmanos Cancer Institute owes a debt of gratitude to that 50-year-old law for providing necessary funding that makes such research possible.

“The Karmanos Cancer Institute became one of the NCI designated cancer centers,” Dr. Bepler said. “Very quickly, the National Cancer Institute realized just having one cancer institute in Bethesda, Maryland alone wouldn’t be able to achieve that high goal of eradicating cancer. This network established cancer centers throughout the United States.” What started as a couple of centers in the 1970s is now more than 50 comprehensive cancer centers.

The world now possesses many drugs and treatments to treat cancer through the dedication and research of institutes like the Karmanos Center. And some research led to treatments for other diseases. Dr. Bepler mentioned the Karmanos Center developed three of the first FDA-approved AIDS drugs.

More Like This Story:

The Rising Tide of Food Allergens

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Book a Demo →Talk to Sales

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

Book a Demo →Try it Free

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agreed to acquire most of Vantive's hemodialysis business for $125 million in base consideration, plus up to $45 million in contingent payments, with closing expected mid-2027. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility; the combined business could generate $400-450 million annually, depending on various factors.

  • 01Rockwell Medical acquires Vantive's hemodialysis concentrates, AK 98 machines, water treatment systems, and one-million-square-foot Medolla, Italy manufacturing campus for $125 million base price plus up to $45 million contingent on revenue and EBITDA milestones.
  • 02Combined business targeted to generate $400-450 million in annual revenue depending on operating performance, exchange rates, market conditions and integration.
  • 03Vantive's dialyzer portfolio, including Theranova dialyzer for expanded hemodialysis, remains with Vantive; the company will focus on home dialysis and critical care after divestiture.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For Healthcare teams

See how Healthcare teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Healthcare

Healthcare hubMore expert Healthcare coverage.Explore →Executive Thought LeadershipPut clinical leaders on the record.Explore →CooperVisionMedical device storytelling.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512